Partnerships in Proteomics and Immune Monitoring
Caprion continues to grow our network of trusted partners, especially throughout North America and Europe. In additional to the 50+ biotech and pharmaceuticals companies we help to advance their therapeutic programs, Caprion has been trusted with scientific leadership roles in government and academic institutions to accelerate therapeutic advancements in neurological disease, infections disease, and oncology.
Below is a listing of our partners, and brief descriptions of their mission and our role. We are honored for the opportunity to apply our proteomics and immune monitoring expertise both nationally and internationally.
- Biomarker Consortium
- European Association for Cancer Immunotherapy (CIMT)
- Personalized Medicine Partnership for Cancer (PMPC)
- The National Institute of Allergy and Infectious Diseases (NIAID)
- External Quality Assurance Program Oversight Laboratory (EQAPOL)
The Foundation for the National Institutes of Health's (NIH) Biomarker Consortium
The Biomarkers Consortium is a major public-private biomedical research partnership managed by the Foundation for the National Institutes of Health with broad participation from stakeholders across the health field, including government, industry, academia and patient advocacy and other non-profit private sector organizations. The Biomarkers Consortium brings together the expertise and resources of various partners to rapidly identify, develop, and qualify potential high-impact biomarkers particularly to enable improvements in drug development, clinical care, and regulatory decision-making.
Working in conjunction with the Biomarker Consortium as the selected discovery partner, Caprion has developed CNS ProteoCarta™, an easily customizable and highly multiplexed mass spectrometry based assay, useful in monitoring central nervous system (CNS) proteins associated with neurological disorders such as Alzheimer’s Disease and Parkinson’s Disease. Caprion and The Biomarkers Consortium continue to further enhance offerings for neurological disorders and other therapeutic areas.
Quebec Consortium for Drug Discvoery (CQDM)
The Quebec Consortium for Drug Discvoery (CQDM) is a research consortium consistent of government and private entities, driven by the mission to fund the development of breakthrough tools and technologies that enhance biopharmaceutical R&D productivity, and accelerate the development of safer and more effective drugs.
Caprion is investigating the mechanisms resulting in neuroendocrine tumor hyper-secretion, to identify and validate diagnostic and prognostic biomarkers for clinical treatment of neuroendocrine tumors. Our large-scale proteomics platform, ProteoCarta, will identify candidate protein biomarkers that display reproducible, condition-specific expression changes.
European Association for Cancer Immunotherapy (CIMT)
The Association for Cancer Immunotherapy (CIMT) is a members-based information and education platform that facilitates the knowledge exchange between academic and industry scientists, physicians and regulatory authorities who research and develop cancer immunotherapies.
Caprion will be participating in the development and assessment of novel cancer immunotherapies through its experience in immune monitoring. ImmuneCarta has been involved in numerous immuno-oncology trials and aims to further this experience with its partnership with CIMT.
Personalized Medicine Partnership for Cancer (PMPC)
The Personalized Medicine Partnership for Cancer (PMPC) is a public-private partnership focused on establishing an integrated approach for the development and implementation of clinical biomarkers and other personalized healthcare solutions. PMPC strives to improve the outcome and cost-efficiency of healthcare services provided to cancer patients in the province of Québec and abroad.
Caprion is leading the integration of our advanced technology platforms with clinical research to provide increasingly targeted treatments for cancer. Caprion's two business units, ImmuneCarta and ProteoCarta, work hand-in-hand to accelerate precision medicine through proteomics and immune monitoring.
The National Institute of Allergy and Infectious Diseases (NIAID)
The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 60 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world. NIAID is one of the 27 Institutes and Centers of the National Institutes of Health (NIH).
Caprion has been awarded two consecutive 5-year US$13 million contracts for Biodefense proteomics research in the area of infectious diseases. ProteoCarta, our gel-free, label-free mass spectrometry technology that enables a comprehensive, quantitative and robust measurement of the protein expression differences across large data sets of biological samples, will help improve the quality of life and health for people.
External Quality Assurance Program Oversight Laboratory (EQAPOL)
The External Quality Assurance Program Oversight Laboratory (EQAPOL) is a National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)-Division of AIDS (DAIDS) funded resource located at the Duke Human Vaccine Institute's (DHVI) Immunology and Virology Quality Assessment Center (IVQAC) to support the development, implementation and oversight of external quality assurance programs that monitor laboratories involved in HIV/AIDS research and vaccine trials around the world.
Caprion is involved in international proficiency programs that aim to harmonize immune monitoring assays across multiple testing sites. We have been involved in multiple rounds of proficiency testing and are actively participate in all aspects involved with the development of robust immune monitoring assays.